Profil
Karin Ann Thacker formerly worked at Puma Biotechnology, Inc., as Senior Director & Head-Regulatory Development from 2015 to 2016, Harpoon Therapeutics, Inc., as VP-Regulatory Affairs & Quality Assurance from 2020 to 2022, Gritstone bio, Inc., as Vice President-Global Regulatory Affairs from 2019 to 2020, and Senti Biosciences, Inc., as Vice President-Quality & Regulatory Affairs.
Ms. Thacker received her undergraduate degree and graduate degree from the University of Manitoba.
Anciens postes connus de Karin Ann Thacker
| Sociétés | Poste | Fin |
|---|---|---|
Senti Biosciences, Inc.
Senti Biosciences, Inc. BiotechnologyHealth Technology Develops a synthetic biology platform that enables to program next-generation cell and gene therapies | Conseiller Juridique Général | 01/05/2024 |
| HARPOON THERAPEUTICS, INC. | Conseiller Juridique Général | 01/08/2022 |
| GRITSTONE BIO, INC. | Conseiller Juridique Général | 01/08/2020 |
| PUMA BIOTECHNOLOGY, INC. | Corporate Officer/Principal | 01/05/2016 |
Formation de Karin Ann Thacker
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
University of Manitoba
University of Manitoba Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Puma Biotechnology, Inc.
Puma Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer | Health Technology |
Gritstone bio, Inc.
Gritstone bio, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapies for cancer | Health Technology |
Harpoon Therapeutics, Inc.
Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage immunotherapy company that develops T-cell engagers to treat cancer and other diseases | Health Technology |
Senti Biosciences, Inc.
Senti Biosciences, Inc. BiotechnologyHealth Technology Develops a synthetic biology platform that enables to program next-generation cell and gene therapies | Health Technology |
















